Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes

NCT: NCT07034261 · NOT_YET_RECRUITING

NCT IDNCT07034261
StatusNOT_YET_RECRUITING
Start Date2026-09
Completion2027-09
SponsorUniversity of Chicago (OTHER)
First posted
Last updated

Brief Summary

The aim of this study is to determine the ability of postpartum continuous glucose monitoring (CGM) for subjects with gestational diabetes (GDM) to predict dysglycemia on 4-12 week postpartum oral glucose tolerance test (OGTT).

Frequently Asked Questions

What is Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes?

Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes is a clinical trial registered under NCT07034261. Current status: NOT_YET_RECRUITING.

What is the status of NCT07034261?

The current status of NCT07034261 (Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes) is: NOT_YET_RECRUITING.

When did Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes start?

Continuous Glucose Monitoring to Detect Postpartum Dysglycemia in Patients With Gestational Diabetes started on 2026-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑